- Molecular NameDisopyramide
- SynonymDisopiramida [INN-Spanish]; Disopyramide Free Base; Disopyramide Phosphate; Disopyramidum [INN-Latin]
- Weight339.483
- Drugbank_IDDB00280
- ACS_NO3737-09-5
- Show 2D model
- LogP (experiment)2.71
- LogP (predicted, AB/LogP v2.0)2.72
- pka10.4
- LogD (pH=7, predicted)0.48
- Solubility (experiment)6.77 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-0.77
- LogSw (predicted, AB/LogsW2.0)1.39
- Sw (mg/ml) (predicted, ACD/Labs)0.17
- No.of HBond Donors2
- No.of HBond Acceptors4
- No.of Rotatable Bonds8
- TPSA59.22
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antiarrhythmic medication. It is a Class Ia antiarrhythmic (sodium channel blocker) used in the treatment of ventricular tachycardias.
- Absorption_value95.0
- Absorption (description)Rapidly and almost completely absorbed after oral administration and widely distributed throughout the body.
- Caco_2N/A
- Bioavailability83.0
- Protein binding57.5
- Volume of distribution (VD)0.7 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmThe major metabolite, N-monodesisopropyldisopyramide, is about one half as active as disopyramide.
- Half life3~11 h (dose-dependent), increased in subjects with renal impairment; desalkyl metabolite about 13 h.
- ExcretionUp to about 50 to 60% of a dose is excreted in the urine in 5 days as unchanged drug, with about 20 to 30% as the desalkyl metabolite; about 10 to 15% of a dose is eliminated in the faeces.
- Urinary ExcretionN/A
- Clerance0.5~2 ml/min/kg (dose-dependent); unbound drug about 6 mL/min/kg.
- ToxicityToxic effects are usually associated with plasma concentrations greater than about 8 mg/L.
- LD50 (rat)LD50=580 mg/kg
- LD50 (mouse)N/A